ClinicalTrials.gg
CompletedNCT06362642Updated Nov 13, 2024

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants

A Phase 1 interventional study of PC14586 and Itraconazole in Healthy Volunteers, sponsored by PMV Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-13.

Sponsored by PMV Pharmaceuticals, Inc · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effect of PC14586 pharmacokinetics when co administered with itraconazole in healthy participants.

Read the detailed description

PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.

This is a Phase 1, open-label, fixed-sequence study to investigate the effect of coadministration of itraconazole on the pharmacokinetics (PK) of PC14586 (rezatapopt) in healthy male and female participants. Potential participants will be screened to assess their eligibility to enter the study within 56 days prior to the first dose administration. Participants will be admitted into the study site on Day -1 and be confined to the study site until discharge on Day 33. Participants will return to the study site for PK sample collection on Day 37 and a follow-up visit and PK sample collection on Day 42.

Approximately 16 participants will be enrolled in this study.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Y220C
  • PC14586
  • PMV Pharma
  • PMV
  • itraconazole
  • rezatapopt
  • Phase 1
  • CYP3A4
03

In context

Lead sponsor

PMV Pharmaceuticals, Inc is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, non-smoking males and females, aged 18-55 years of age, with between 18.0 and 32.0 kg/m2 inclusive.
  2. In good health, determined by no findings from medical history and evaluations at screening and check-in as assessed by the investigator.
  3. Females of non-, males who agree to a highly effective method of from first dose through 3 months after end of study visit.
  4. Participants who are able to swallow tablets and capsules.
  5. Participants who are capable and willing of giving signed .

Exclusion criteria

Exclusion Criteria:

  1. Participants with significant medical history or clinical manifestation of any medical condition, disease or disorder, as determined by the investigator.
  2. History of significant , intolerance, or allergy to itraconazole or any of the or to medicinal products with similar chemical structures, food or other substance.
  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
  4. Participant has blood pressure >140 mmHg systolic or >90 mmHg diastolic at screening or Day -1.
  5. Prolonged corrected for heart rate using Fridericia's correction >450 ms for males and >470 ms for females at screening.
  6. Positive hepatitis panel and/or positive test.
  7. Abnormalities in liver function test or AST >1.5 × .
  8. Administration of any vaccine including coronavirus disease 2019 vaccine in the past 14 days prior to check-in.
  9. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to check-in.
  10. Use or intend to use any prescription medications/products or any nonprescription medications/products within 14 days prior to check-in.
  11. Participation in a clinical study involving last administration of an drug (new chemical entity) in the past 30 days prior to dosing, or within 5 half-lives of the IMP, whichever is longer, or have previously received PC14586.
  12. Participant has a history of alcohol or drug/chemical abuse within 2 years prior to check-in and/or is unwilling to avoid use of caffeine or alcohol or caffeine-containing foods or alcohol-containing foods, medications, or beverages, within 48 hours prior to check-in until the follow up visit.
  13. Use of tobacco- or nicotine-containing products (cigarettes, snuff, chewing tobacco, cigars, pipes, vaporizer, or nicotine-replacement products such as nicotine chewing gum and nicotine patches) within 3 months prior to check-in, or positive cotinine at screening or check-in.
  14. Participants with a germline TP53 Y220C mutation at Screening.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    PC14586 and Itraconazole

    Healthy participants will receive a single, oral dose of PC14586 on day 1. On day 20, participants will receive BID oral doses of itraconazole. On days 21-22, participants will receive a single, oral dose of itraconazole. On day 23, participants will receive a single, oral dose of PC14586 and a single oral dose of itraconazole. On days 24-27, participants will receive a single, oral dose of itraconazole.

    Drug: PC14586 · Drug: Itraconazole

Interventions

  • First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.

    Also known as: rezatapopt

  • Antifungal treatment that is a potent inhibitor of CYP3A4.

06

What researchers measure

Primary outcomes

  1. Characterize the Maximum Plasma Concentration (Cmax) of PC14586 when co-administered with itraconazole in healthy participants.

    Determine the Cmax of PC14586 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  2. Characterize the total drug exposure (AUC0-inf) of PC14586 when co-administered with itraconazole in healthy participants.

    Determine the AUC0-inf of PC14586 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  3. Characterize the time to peak drug concentration (Tmax) of PC14586 when co-administered with itraconazole in healthy participants.

    Determine the Tmax of PC14586 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  4. Characterize the total drug exposure from time zero to 24 hours (AUC0-24) of PC14586 when co-administered with itraconazole in healthy participants.

    Determine the AUC0-24 of PC14586 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  5. Characterize the total drug exposure from time zero to the last timepoint (AUC0-t) of PC14586 when co-administered with itraconazole in healthy participants.

    Determine the AUC0-t of PC14586 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  6. Characterize the half-life (t1/2) of PC14586 when co-administered with itraconazole in healthy participants.

    Determine the t1/2 of PC14586 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

Secondary outcomes

  1. Characterize the Maximum Plasma Concentration (Cmax) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.

    Determine the Cmax of PC14586 metabolites M13 and M14 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  2. Characterize the total drug exposure (AUC0-inf) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.

    Determine the AUC0-inf of PC14586 metabolites M13 and M14 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  3. Characterize the time to peak drug concentration (Tmax) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.

    Determine the Tmax of PC14586 metabolites M13 and M14 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  4. Characterize the total drug exposure from time zero to 24 hours (AUC0-24) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.

    Determine the AUC0-24 of PC14586 metabolites M13 and M14 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  5. Characterize the total drug exposure from time zero to the last timepoint (AUC0-t) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.

    Determine the AUC0-t of PC14586 metabolites M13 and M14 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  6. Characterize the half-life (t1/2) of PC14586 metabolites M13 and M14 when co-administered with itraconazole in healthy participants.

    Determine the t1/2 of PC14586 metabolites M13 and M14 when co-administered with itraconazole in plasma.

    Time frame: 6 weeks

  7. Identification of the incidence of treatment emergent adverse events (TEAE) of PC14586 when administered alone and co-administered with itraconazole in healthy participants.

    Identify the incidence of TEAEs of PC14586 alone or when co-administered with itraconazole.

    Time frame: 6 weeks

  8. Identification of vital sign abnormalities after administration of PC14586 alone and when co-administered with itraconazole in healthy participants.

    Identify the number of participants with abnormal vital signs.

    Time frame: 6 weeks

  9. Identification of 12-lead electrocardiogram (ECG) abnormalities after administration of PC14586 alone and when co-administered with itraconazole in healthy participants.

    Identify the number of participants with abnormal ECG results.

    Time frame: 6 weeks

  10. Identification of laboratory abnormalities based on hematology and clinical chemistry after administration of PC14586 alone and when co-administered with itraconazole in healthy participants.

    Identify the number of participants with an incidence of laboratory abnormalities in test results.

    Time frame: 6 weeks

07

Study locations

1 site
  • Fortrea
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Oct 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 12, 2024
StartActual
Mar 28, 2024
Primary completionActual
Oct 22, 2024
CompletionActual
Oct 22, 2024
Last update
Nov 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06362642
Lead sponsor
PMV Pharmaceuticals, Inc
Responsible party
Sponsor
First posted
Apr 12, 2024
Start date
Mar 28, 2024
Primary completion
Oct 22, 2024
Completion
Oct 22, 2024
Last update
Nov 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezatapopt

Start the discussion